CGEM
NASDAQ
US
Cullinan Therapeutics, Inc. - Common Stock
$14,43
▲ +$0,49
(+3,52%)
Vol. 1.1M
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$611.4M
ROE
-41,6%
D/E
0,00
Beta
-0,06
52W
$6–$13
Consenso Wall Street
19 analisti · Apr 20269
Acquisto forte
9
Compra
1
Mantieni
0
Vendi
0
Vendita forte
94,7%
Rating Compra
Grafico dei Prezzi
Titoli simili
Utili
Tasso di battuta: 80,0%
Prossimo report
Mag 06, 2026
Stima EPS: $-0,84
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-0,84 | — | — |
| Dic 2025 | $-0,83 | $-0,77 | +$0,06 |
| Set 2025 | $-0,98 | $-0,77 | +$0,21 |
| Giu 2025 | $-0,85 | $-1,07 | $-0,22 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | — | — | — | — | — |
| Utile netto | — | -$47.6M | -$48.5M | -$70.1M | -$50.6M | -$50.7M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -36.6% | -36.6% | -36.6% | -36.6% | -41.6% | -41.6% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 9.83 | 9.83 | 9.83 | 9.83 | 10.45 | 10.45 |
Rapporti chiave
ROA (TTM)
-39,3%
P/B
1,2
EPS (TTM)
$-3,68
CF/Share
$-3,70
52W High
$13,33
52W Low
$5,68
$5,68
Intervallo 52 settimane
$13,33
Salute finanziaria
Flusso di cassa libero
-$38.1M
Debito netto
-$85.6M
Liquidità
$88.3M
Debito totale
$2.7M
Aggiornato al Dic 31, 2025
Як CGEM виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка CGEM vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
—
▼
0%
sotto
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
1,2
▼
51%
sotto
peer
(2,5)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість CGEM vs аналоги Biotechnology
ROE
-41,6%
▲
38%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
—
▼
0%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Top livello
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-39,3%
▲
16%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя CGEM vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
10,5
▲
135%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
-0,1
▼
106%
sotto
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів CGEM
CGEM
Mediana peer
Industria
CGEM прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
CGEM vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
MICHAELSON JENNIFER
Officer · Mar 05
8000 shs
MICHAELSON JENNIFER
Officer · Mar 05
4000 shs
MICHAELSON JENNIFER
Officer · Feb 25
1780 shs
AHMED NADIM
Chief Executive Officer · Feb 24
13515 shs
MICHAELSON JENNIFER
Officer · Feb 24
5353 shs
SUMER JACQUELYN L
Officer · Feb 24
3601 shs
JONES JEFFREY ALAN
Officer · Feb 24
4582 shs
FENTON MARY KAY
Chief Financial Officer · Feb 20
4398 shs
AHMED NADIM
Chief Executive Officer · Feb 20
16381 shs
MICHAELSON JENNIFER
Officer · Feb 20
11742 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 49,67%Lynx1 Capital Management Lp
14,81%
$115.2M
MPM Bioimpact LLC
12,64%
$98.3M
BVF Inc.
9,50%
$73.9M
Blackrock Inc.
7,27%
$56.5M
Vanguard Group Inc
5,45%
$42.4M
Aggiornato al Dic 31, 2025